Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:NTLANASDAQ:REGNNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$36.99-5.8%$37.24$30.04▼$67.88$3.19B1.881.68 million shs2.00 million shsNTLAIntellia Therapeutics$9.20-4.9%$7.99$5.90▼$28.18$952.96M2.332.54 million shs4.18 million shsREGNRegeneron Pharmaceuticals$604.62-1.7%$595.54$520.50▼$1,211.20$65.28B0.43792,444 shs1.09 million shsVRTXVertex Pharmaceuticals$435.32-2.7%$479.38$377.85▼$519.88$111.79B0.511.41 million shs1.43 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-5.76%+3.90%-2.19%-26.69%-32.45%NTLAIntellia Therapeutics-4.86%+16.75%+16.16%-24.90%-64.22%REGNRegeneron Pharmaceuticals-1.65%+5.82%+7.68%-13.13%-39.17%VRTXVertex Pharmaceuticals-2.65%+3.36%-8.84%-9.37%-1.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.0536 of 5 stars4.31.00.00.02.63.30.6NTLAIntellia Therapeutics4.6356 of 5 stars4.31.00.04.73.82.51.3REGNRegeneron Pharmaceuticals4.8009 of 5 stars4.53.01.72.33.31.71.9VRTXVertex Pharmaceuticals4.6182 of 5 stars3.35.00.03.34.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7593.97% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$36.90301.09% UpsideREGNRegeneron Pharmaceuticals 2.92Moderate Buy$890.6047.30% UpsideVRTXVertex Pharmaceuticals 2.59Moderate Buy$515.0418.31% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, VRTX, NTLA, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/14/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$600.00 ➝ $700.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M91.27N/AN/A$22.52 per share1.64NTLAIntellia Therapeutics$45.57M20.91N/AN/A$11.73 per share0.78REGNRegeneron Pharmaceuticals$14.09B4.63$39.70 per share15.23$268.50 per share2.25VRTXVertex Pharmaceuticals$11.10B10.07N/AN/A$63.90 per share6.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%N/AREGNRegeneron Pharmaceuticals$4.41B$39.2815.7915.902.3431.07%16.32%12.76%8/7/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A24.862.11-4.86%-2.02%-1.49%8/7/2025 (Estimated)Latest CRSP, VRTX, NTLA, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.58%N/A8.96%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest CRSP, VRTX, NTLA, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07NTLAIntellia TherapeuticsN/A6.736.73REGNRegeneron Pharmaceuticals0.094.733.95VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%REGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%NTLAIntellia Therapeutics3.10%REGNRegeneron Pharmaceuticals7.02%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableREGNRegeneron Pharmaceuticals11,900107.97 million101.15 millionOptionableVRTXVertex Pharmaceuticals4,800256.80 million256.28 millionOptionableCRSP, VRTX, NTLA, and REGN HeadlinesRecent News About These CompaniesPrincipal Street Partners LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 8:00 AM | marketbeat.comLantern Wealth Advisors LLC Buys 650 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 7:40 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 7:19 AM | marketbeat.comWoodline Partners LP Acquires 16,653 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 6:17 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Vident Advisory LLCMay 22 at 5:59 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lifted by Tidal Investments LLCMay 22 at 5:17 AM | marketbeat.comVertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?May 21 at 4:44 PM | msn.comWestport Asset Management Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 7:15 AM | marketbeat.comTriglav Skladi D.O.O. Takes $1.39 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 6:55 AM | marketbeat.comTwinbeech Capital LP Purchases New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 6:54 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Silvercrest Asset Management Group LLCMay 21 at 5:42 AM | marketbeat.comTema Etfs LLC Takes $4.42 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 6:16 AM | marketbeat.comToronto Dominion Bank Has $43.42 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 6:15 AM | marketbeat.comSnowden Capital Advisors LLC Has $1.91 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 5:58 AM | marketbeat.comInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 52 Shares of StockMay 20 at 5:18 AM | insidertrades.comVRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue MissMay 20 at 3:45 AM | msn.comVertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy RatingMay 19 at 7:24 AM | tipranks.comRoyal Bank of Canada Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 19 at 6:13 AM | marketbeat.comQuantinno Capital Management LP Has $9.70 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 18, 2025 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Man Group plcMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBig Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025By Nathan Reiff | May 15, 2025View Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseBy Chris Markoch | May 16, 2025View CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseCRSP, VRTX, NTLA, and REGN Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$36.99 -2.26 (-5.76%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$36.82 -0.17 (-0.46%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$9.20 -0.47 (-4.86%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$9.06 -0.14 (-1.47%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Regeneron Pharmaceuticals NASDAQ:REGN$604.62 -10.17 (-1.65%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$601.76 -2.87 (-0.47%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$435.32 -11.86 (-2.65%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$433.40 -1.92 (-0.44%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? $30B AI Opportunity: Will It Power Meta’s Next Surge? Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
